Drug combination for stage IV melanoma shows success in trial



Drug combination for stage IV melanoma shows success in trial

A new study examined the combination of the common immunotherapy drug pembrolizumab (Keytruda) with all-trans retinoic acid (ATRA), a chemotherapy drug that targets myeloid-derived suppressor cells. Researchers found that the drug combination is effective, with an overall response rate of 71%. Fifty percent of patients experienced a complete response, and the one-year overall survival rate was 80%.

Materials provided by University of Colorado Anschutz Medical Campus. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

1st June 2023

Open-analysis platform for pediatric brain tumors provides robust data resource for childhood cancer research

Read more
31st May 2023

Plants remove cancer causing toxins from air

Read more
31st May 2023

How the flu virus hacks our cells

Read more